Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study

摘要

BACKGROUND: In PATENT-1, riociguat significantly improved 6-minute walking distance (6MWD) pulmonary arterial and a range of secondary end-points in patients with pulmonary arterial hypertension (PAH). We hypertension; investigated whether riociguat increased the proportion of patients achieving clinically relevant riociguat; responder thresholds compared with placebo during PATENT-1. soluble guanylate